Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)

HHS-NIH11 PAR-26-064
Submission: Open Submission

CFDA Numbers

  • 93.395 - Cancer Treatment Research

Additional Information

Document Type: forecast
Opportunity Category: Discretionary

Related Opportunities